Stocks / Stock overview

Evommune, Inc. (EVMN)

$13.23-1.85%Aft $13.23 (+0.00%)Market cap $480.1M

NYSE · Price as of · Delayed Quote

Stock Scorer
Scoring…
Analyst consensus
Buy$27.63
  • Analysts8
  • Implied upside+108.8%
  • Target range$22.00 to $32.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 16, 2026date estimated
  • EPS expected-$0.83
  • A year ago-$8.07
  • Revenue expected$333,330 -97%
  • Estimate range-$1.01 to -$0.63
Consensus of 10 analysts for the quarter ending September 30, 2026. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
SCHEDULE 13G/AAugust 14, 2026View on EDGAR
SCHEDULE 13GAugust 14, 2026View on EDGAR
424B3August 6, 2026424B3
10-QAugust 6, 202610-Q
8-KAugust 6, 20268-K
8-KJuly 30, 20268-K
SCHEDULE 13GJuly 16, 2026View on EDGAR
4July 10, 2026PRIMARY DOCUMENT
All SEC filings

Articles that mention Evommune without it being the main subject.

What is a pod shop? Millennium didn't buy your stock. One of its 340 teams did.
Explainers

What is a pod shop? Millennium didn't buy your stock. One of its 340 teams did.

Citadel's last quarterly filing listed 15,589 positions. Millennium runs more than 340 separate investment teams and Point72 more than 200, which changes what a hedge fund stake in your stock actually means.

Jul 25, 2026

Frequently asked questions

When does EVMN report earnings?

Evommune, Inc. (EVMN) is scheduled to report quarterly results on November 16, 2026 (estimated). The 10-analyst consensus is -$0.83 per share on revenue of $333,330 for the quarter ending September 30, 2026, against -$8.07 and $10.0M a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for EVMN?

8 analysts cover Evommune, Inc. (EVMN). The consensus rating is Buy. The average price target is $27.63, in a range of $22.00 to $32.00.

Are insiders buying or selling EVMN?

We have no qualifying Form 4 insider purchases or sales on record for Evommune, Inc. (EVMN). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see EVMN SEC filings?

Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G/A filed August 14, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.